Repligen Corporation (NASDAQ:RGEN) to Release Q2 2009 Earnings November 6

Repligen Corporation (NASDAQ:RGEN) will release the second quarter earnings for 2009 on Thursday, November 6.  Repligen President and chief Executive Officer Walter C. Herlihy will hold a conference call that morning at 10:00 am ET to discuss the financial results.  An audio webcast of the conference call will be available on the company’s website, repligen.com.  Interested parties may also hear the call via phone by dialing 866-825-3209 or 617-213-8061 for international callers.

Repligen Corporation (Repligen) develops therapeutics for the treatment of diseases of the central nervous system. The Company sells a line of Protein A, which is used in the production of monoclonal antibodies, and SecreFlo, a synthetic form of the hormone secretin, which is used as an aid in the diagnosis of certain diseases of the pancreas.

The Company sells its Protein A products primarily through value-added resellers, including GE Healthcare (GEHC) and Applied Biosystems, Inc., as well as through distributors in certain foreign markets. It markets SecreFlo directly to gastroenterologists in the United States. The Company also owns intellectual property on monoclonal antibody and antibody fusion products.

Read more Business News on The Global Market Directory.

About The Global Market Directory (TheGMD)

TheGMD is a financial networking community for Public Companies, Brokerage Firms, Stock Brokers and Individuals. Members can network and link with each other, participate in discussions on financial stock message boards, display pictures and upload videos.

The GMD is a member of the TransWorldNews, Inc. family of sites. Members can distribute press releases through The GMD and receive distribution over all TransWorldNews news outlets.

Create your profile on The Global Market Directory